LIVMARLI® Global Availability
The first approved treatment for cholestatic pruritus in patients with Alagille syndrome (ALGS).
LIVMARLI has also been approved by the FDA for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (PFIC) 12 months of age and older. LIVMARLI has been authorized by the European Commission for the treatment of PFIC in patients three months of age and older. See where LIVMARLI is now approved.*
*Approval through country regulatory agencies; commercialized by Mirum or partner/distributor.
Alagille syndrome (ALGS)
Treatment of cholestatic pruritus in patients 3 months of age and older with ALGS
Prescribing Information and Important Safety InformationEuropean Union
Treatment of cholestatic pruritus in patients 2 months of age and older with ALGS
SMPCCanada
Treatment of cholestatic pruritus in patients 12 months or older with ALGS
China1
Treatment of cholestatic pruritus in patients 3 months and older with ALGS
Israel2
Treatment of cholestatic pruritus in patients 1 year of age and older with ALGS
South Korea3
Treatment of cholestatic pruritus in patients 1 year and older with ALGS
and older
1. Approved through country regulatory agencies; commercialized by partner, CANbridge.
2. Approved through country regulatory agencies; commercialized by distributor partner, Neopharm.
3. Approved through country regulatory agencies; commercialized by partner, GC Pharma.
Progressive familial intrahepatic cholestasis (PFIC)
Treatment of cholestatic pruritus in patients 12 months of age and older with PFIC
Limitations of Use: LIVMARLI is not recommended in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of bile salt export pump (BSEP) protein.
Prescribing information and important safety informationEuropean Union
Treatment of PFIC in patients 3 months of age and older
SMPC
Canada
Treatment of cholestatic pruritus in patients 12 months or older with PFIC
